#Germany #Berlin #Lutetium-177 #Eckert Ziegler #AtomVie

Eckert Ziegler and AtomVie Global Radiopharma Sign Global Supply Agreement for Lutetium-177

In a notable advancement in the field of radiopharmaceuticals, Eckert Ziegler SE and AtomVie Global Radiopharma Inc. have entered into a comprehensive global supply agreement for Lutetium-177, a crucial component in cancer treatment. This partnership, announced on March 20, 2025, sets a new benchmark in the manufacture and distribution of high-quality radiopharmaceuticals, specifically emphasizing the unencumbered supply of Theralugand®, a high-quality Lutetium-177 chloride.

The collaboration encompasses all phases of radiopharmaceutical development, from the initial stages to advanced production. The strategic partnership allows AtomVie to access Theralugand® reliably, which is essential for the continuous development of Lu-177-based radiopharmaceuticals at their facilities. This agreement's flexibility enables both companies to adapt swiftly to the varying needs of pharmaceutical partners during the development and commercialization of these critical therapeutics, while also ensuring compliance with global regulatory standards.

Dr. Harald Hasselmann, CEO of Eckert Ziegler SE, expressed enthusiasm about the collaboration, stating, "We are pleased to support AtomVie in advancing global radiopharmaceutical development programs with Theralugand®. By providing our high-quality radionuclides, we make a vital contribution to the evolution of therapeutic approaches in nuclear medicine."

Bruno Paquin, CEO of AtomVie, also shared his thoughts, noting, "Partnering with Eckert Ziegler is a significant milestone that guarantees our global partners developing Lu-177-based radiopharmaceuticals the support they need. With the commissioning of our new facilities later this year, this collaboration strengthens our ability to deliver reliable and high-quality manufacturing services. Together with our partners, we look forward to driving innovation and transforming patient care."

About Eckert Ziegler SE

With a workforce of over 1,000 employees, Eckert Ziegler SE has established itself as a leading specialist in isotopic components for nuclear medicine and radiotherapy. The company provides a wide array of services and products tailored to the radiopharmaceutical industry, ranging from initial development to contract manufacturing and distribution. Eckert Ziegler's shares (ISIN DE0005659700) are traded on the TecDAX of the German Stock Exchange, emphasizing its prominent position in the market.

About AtomVie Global Radiopharma Inc.

AtomVie is recognized as a global leader in the manufacturing of GMP-certified radiopharmaceuticals and the worldwide distribution of clinical and commercial radiopharmaceutical products. The company boasts a comprehensive suite of scientific, technical, regulatory, quality, and logistical services, combined with specialized infrastructure for the development of radiopharmaceuticals, from clinical trials to market launch. AtomVie currently serves international clients conducting studies across more than 25 countries, significantly enhancing access to innovative treatments for patients worldwide.

For more information on the latest developments, visit Eckert Ziegler and AtomVie.